2007-12-08-世界卫生组织-INN_Proposed_List_98_52页_402kb

Proposed INN List 98 Summary

This document lists proposed International Nonproprietary Names (INN) for pharmaceutical substances. Each name includes its chemical structure, action, use, and CAS registry number. The names are grouped alphabetically:

• Adipiplčnum: Sedative, hypnotic with specific chemical structure.
• Agatolimodum: Antineoplastic properties.
• Alacizumabum: Monoclonal antibody targeting VEGFR2; used in oncology.
• Amolimogenum bepiplasmidum: Immunomodulator for HPV-related conditions.
• Amsilarotenum: Antineoplastic treatment.
• Anacetrapibum: Antihyperlipidaemic agent.
• Anrukinzumabum: Immunomodulator targeting interleukin 13.
• Baminerceptum: Immunomodulator for tumor necrosis factor.
• Bentamapimodum: Immunomodulator.
• Berubicinum: Antineoplastic antibiotic.
• Besifloxacinum: Antibacterial agent.
• Betrixabanum: Blood coagulation factor Xa inhibitor.
• Briobaceptum: Immunomodulator for BAFF receptor.
• Cabazitaxelum: Antineoplastic substance for cancer treatment.
• Cariprazinum: Antipsychotic agent.
• Carmegliptinum: Hypoglycaemic drug.
• Cobiprostonum: Prostaglandin derivative for GI protection.
• Conestatum alfa: Enzyme inhibitor for plasma protease c1.
• Dacetuzumabum: Antineoplastic monoclonal antibody targeting CD40.
• Daporinadum: Antineoplastic substance for triple-negative breast cancer.
• Darinaparsinum: Antineoplastic treatment.
• Deforolimusum: Immunosuppressive mTOR inhibitor.
• Dexnebivololum: Beta-adrenoreceptor antagonist for hypertension.
• Emricasanum: Caspase inhibitor for liver disease.
• Eribaxabanum: Factor Xa inhibitor for thrombosis.
• Ezatiostatum: Glutathione-S-transferase inhibitor.
• Fasobegronum: Beta-adrenoreceptor agonist for weight loss.
• Favipiravinum: Antiviral agent.
• Fer</font>magatum</u></font>: Phosphate binder for hyperphosphatemia.
• Flopristinum: Antibacterial agent.
• Folitixorinum: Folate derivative for mTOR inhibition.
• Ibodutantum: Tachykinin receptor antagonist for pain management.
• Imegliminum: Hypoglycaemic drug for diabetes.
• Laromustinum: Antineoplastic agent.
• Levonebivololum: Beta-adrenoreceptor antagonist for hypertension.
• Linopristinum: Antibacterial agent.
• Lucatumumabum: Monoclonal antibody targeting CD40 for cancer.
• Milatuzumabum: Monoclonal antibody for CD74 in cancer.
• Mirabegronum: Beta-adrenoreceptor agonist for overactive bladder.
• Monepantelum: Antiparasitic agent for veterinary use.
• Nelivaptanum: Vasopressin receptor antagonist for hyponatremia.
• Nesbuvirum: Antiviral agent.
• Od</font>anacatibum</u></font>: Cathepsin inhibitor.
• Otelixizumabum: Monoclonal antibody for CD3 targeting immature T cells.
• Pegloticasum: Recombinant uricase for hyperuricemia.
• Preladenantum: Adenosine receptor antagonist for respiratory conditions.
• Quarfloxinum: Antineoplastic agent.
• Radiprodilum: NMDA receptor antagonist for ischemia.
• Remogliflozini etabonas: SGLT2 inhibitor as etabonate salt.
• Retosibanum: Oxytocin antagonist for premature labor.
• Riociguatum: GC-C receptor agonist for C. diff.
• Rolo</font>ffyllinum</u></font>: Nootropic agent.
• Tenatum</u></font>omabum</font>: Monoclonal antibody for tenascin C in cancer.
• Tigatuzumabum: Monoclonal antibody for DR5 in cancer.
• Tiprol</u></font>isantum</font>: Histamine H3 receptor antagonist for allergies.
• Velaglucerase alfa: Glucosylceramidase for Gaucher's disease.
• Veltuzumabum: Monoclonal antibody targeting CD20 for lymphoma.
• Viqu</u></font>idacinum</font>: Antibacterial agent.

Amendments to Previous Lists: Refers to corrections made to earlier INN lists (e.g., Nebivololum, Beroctocogum Alfa) and inclusion of new names like Sergliflozini Etabonas.

Procedural and General Principles: The document includes detailed appendices on the selection process and guidelines for devising INN, which are not part of the proposed names but provide context for the INN system.